Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 11/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24266306 | 1.00 | HRH3 (0.42) | HRH3HRH1KDM2BJAK2JAK3 | |
| SCHEMBL24266312 | 0.93 | JAK3 (0.41) | HRH3HRH1JAK2JAK3PTK2 | |
| SCHEMBL29397025 | 0.93 | JAK3 (0.44) | JAK2JAK3PTK2PTGS1PTGS2 | |
| SCHEMBL24266195 | 0.93 | JAK3 (0.44) | JAK2JAK3PTK2PTGS1PTGS2 | |
| SCHEMBL30541679 | 0.87 | HRH3 (0.44) | HRH3HRH1KDM2BJAK2JAK3 | |
| SCHEMBL25366282 | 0.87 | HRH3 (0.44) | HRH3HRH1KDM2BJAK2JAK3 | |
| SCHEMBL29396667 | 0.86 | MAP4K1 (0.38) | JAK2JAK3PTK2PTGS1PTGS2 | |
| SCHEMBL24266305 | 0.86 | MAP4K1 (0.38) | JAK2JAK3PTK2PTGS1PTGS2 | |
| SCHEMBL24266709 | 0.84 | CYP17A1 (0.40) | JAK2JAK3PTK2PTGS1PTGS2 | |
| SCHEMBL29399473 | 0.84 | CYP17A1 (0.40) | JAK2JAK3PTK2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4200292-B1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-13 | — | — | EP | claimed |
| EP-4200292-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | claimed |
| CN-116075510-A | 1H-benzo [ d ] imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | 百时美施贵宝公司 | 2023-05-05 | — | — | CN | claimed |
| WO-2022040260-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-24 | — | — | WO | claimed |
| EP-4200292-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-116075510-A | 1H-benzo [ d ] imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | 百时美施贵宝公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2022040260-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-24 | — | — | WO | disclosed |